# Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Canonical URL: https://biopharmsignal.com/news/BJDX/bluejay-diagnostics-announces-closing-of-up-to-23-7-million-private-placement-priced-at-the-market-under-nasdaq-rules
Ticker: BJDX
Company: Bluejay Diagnostics
Source: Bluejay Diagnostics
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.bluejaydx.com
## Summary

$8.5 million upfront with up to approximately $15.2 million of potential additional gross proceeds upon the exercise in full of warrants Net proceeds anticipated to extend cash runway into first quarter of 2027, beyond expected FDA submission; if warrants are exercised in full for cash, it is

## Article Body
$8.5 million upfront with up to approximately $15.2 million of potential additional gross proceeds upon the exercise in full of warrants Net proceeds anticipated to extend cash runway into first quarter of 2027, beyond expected FDA submission; if warrants are exercised in full for cash, it is
## Recent Company News
- 2026-06-25 13:46 EST — [Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules](https://biopharmsignal.com/news/BJDX/bluejay-diagnostics-announces-closing-of-up-to-23-7-million-private-placement-priced-at-the-market-under-nasdaq-rules) — Source: Bluejay Diagnostics
- 2026-06-25 13:46 EST — [Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules](https://biopharmsignal.com/news/BJDX/bluejay-diagnostics-announces-up-to-23-6-million-private-placement-priced-at-the-market-under-nasdaq-rules) — Source: Bluejay Diagnostics
- 2026-06-25 13:46 EST — [Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership](https://biopharmsignal.com/news/BJDX/bluejay-diagnostics-and-argonaut-manufacturing-services-announce-strategic-partnership) — Source: Bluejay Diagnostics
- 2026-06-25 13:46 EST — [Bluejay Diagnostics Provides First Quarter 2026 Corporate Update](https://biopharmsignal.com/news/BJDX/bluejay-diagnostics-provides-first-quarter-2026-corporate-update) — Source: Bluejay Diagnostics
- 2026-06-25 13:46 EST — [Bluejay Diagnostics Announces $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules](https://biopharmsignal.com/news/BJDX/bluejay-diagnostics-announces-4-5-million-private-placement-priced-at-the-market-under-nasdaq-rules) — Source: Bluejay Diagnostics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)